Tower Research Capital (TRC)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,702
| Closed | -$10.1K | – | 6184 |
|
|
2024
Q3 | $10.1K | Sell |
2,702
-494
| -15% | -$2.36K | ﹤0.01% | 3802 |
|
|
2024
Q2 | $17.9K | Sell |
3,196
-352
| -10% | -$1.53K | ﹤0.01% | 3813 |
|
|
2024
Q1 | $18.6K | Sell |
3,548
-3,293
| -48% | -$18.1K | ﹤0.01% | 3063 |
|
|
2023
Q4 | $35.8K | Buy |
6,841
+5,896
| +624% | +$58.2K | ﹤0.01% | 3332 |
|
|
2023
Q3 | $14.9K | Sell |
945
-212
| -18% | -$3.81K | ﹤0.01% | 3650 |
|
|
2023
Q2 | $22.5K | Buy |
1,157
+792
| +217% | +$18.8K | ﹤0.01% | 3281 |
|
|
2023
Q1 | $10K | Buy |
365
+8
| +2% | +$237 | ﹤0.01% | 4430 |
|
|
2022
Q4 | $10K | Sell |
357
-7,600
| -96% | -$242K | ﹤0.01% | 4105 |
|
|
2022
Q3 | $211K | Buy |
7,957
+6,784
| +578% | +$249K | ﹤0.01% | 1881 |
|
|
2022
Q2 | $52K | Sell |
1,173
-1,444
| -55% | -$66.3K | ﹤0.01% | 2849 |
|
|
2022
Q1 | $129K | Sell |
2,617
-1,188
| -31% | -$57K | ﹤0.01% | 2028 |
|
|
2021
Q4 | $194K | Buy |
3,805
+2,654
| +231% | +$138K | ﹤0.01% | 1796 |
|
|
2021
Q3 | $64K | Buy |
1,151
+385
| +50% | +$18.9K | ﹤0.01% | 2767 |
|
|
2021
Q2 | $33K | Sell |
766
-251
| -25% | -$10.4K | ﹤0.01% | 3403 |
|
|
2021
Q1 | $42K | Buy |
1,017
+829
| +441% | +$38.5K | ﹤0.01% | 3278 |
|
|
2020
Q4 | $9K | Sell |
188
-577
| -75% | -$27K | ﹤0.01% | 4409 |
|
|
2020
Q3 | $32K | Sell |
765
-1,301
| -63% | -$56.9K | ﹤0.01% | 3709 |
|
|
2020
Q2 | $99K | Buy |
+2,066
| New | +$103K | ﹤0.01% | 2469 |
|
|
2019
Q1 | – | Sell |
-104
| Closed | -$4K | – | 4390 |
|
|
2018
Q4 | $4K | Buy |
+104
| New | +$5.36K | ﹤0.01% | 3088 |
|
|
2018
Q3 | – | Sell |
-362
| Closed | -$27K | – | 4344 |
|
|
2018
Q2 | $27K | Sell |
362
-1,596
| -82% | -$100K | ﹤0.01% | 2248 |
|
|
2018
Q1 | $103K | Buy |
1,958
+1,712
| +696% | +$99.6K | 0.01% | 1241 |
|
|
2017
Q4 | $13K | Buy |
+246
| New | +$13.7K | ﹤0.01% | 2397 |
|
|
2017
Q2 | – | Sell |
-391
| Closed | -$32K | – | 3589 |
|
|
2017
Q1 | $32K | Sell |
391
-909
| -70% | -$67.6K | ﹤0.01% | 991 |
|
|
2016
Q4 | $103K | Buy |
+1,300
| New | +$94.4K | 0.01% | 962 |
|
|
2016
Q2 | – | Sell |
-30
| Closed | -$1K | – | 5090 |
|
|
2016
Q1 | $1K | Sell |
30
-70
| -70% | -$4.44K | ﹤0.01% | 3823 |
|
|
2015
Q4 | $9K | Sell |
100
-854
| -90% | -$67.4K | ﹤0.01% | 2313 |
|
|
2015
Q3 | $71K | Buy |
+954
| New | +$79.4K | 0.01% | 783 |
|
|
2015
Q2 | – | Sell |
-126
| Closed | -$5K | – | 5152 |
|
|
2015
Q1 | $5K | Sell |
126
-141
| -53% | -$4K | ﹤0.01% | 3283 |
|
|
2014
Q4 | $4K | Sell |
267
-1,699
| -86% | -$21.7K | ﹤0.01% | 2943 |
|
|
2014
Q3 | $25K | Buy |
+1,966
| New | +$24.4K | ﹤0.01% | 2129 |
|
|
2014
Q2 | – | Sell |
-610
| Closed | -$8K | – | 4744 |
|
|
2014
Q1 | $8K | Buy |
+610
| New | +$8.28K | ﹤0.01% | 2864 |
|
Other funds holding EGRX
XT
SLG
AIC
FFA
Tower Research Capital (TRC)'s EGRX Position: Q4 2024 in Review
Tower Research Capital (TRC) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 2,702 shares — an estimated $10.1K sold.
Tower Research Capital (TRC) first reported a position in EGRX in Q1 2014 and held it in 31 quarters. The position peaked at $211K in Q3 2022. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.
- Tower Research Capital (TRC) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,702 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $10.1K.
- Tower Research Capital (TRC) first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 31 quarters.
- Tower Research Capital (TRC)'s Eagle Pharmaceuticals, Inc. position peaked at $211K in Q3 2022.
- 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.